Invo BioScience Net Income 2008-2021 | INVO

Invo BioScience net income from 2008 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Invo BioScience Annual Net Income
(Millions of US $)
2020 $-8
2019 $-2
2018 $-3
2017 $-1
2016 $-2
2015 $-5
2014 $-2
2013 $-1
2012 $-1
2011 $-1
2010 $-0
2009 $-5
2008 $-2
2007 $-0
Invo BioScience Quarterly Net Income
(Millions of US $)
2021-06-30 $-2
2021-03-31 $-2
2020-12-31 $-4
2020-09-30 $-2
2020-06-30 $-1
2020-03-31 $-1
2019-12-31 $-1
2019-09-30 $-1
2019-06-30 $-0
2019-03-31 $-0
2018-12-31 $-1
2018-09-30 $-0
2018-06-30 $-2
2018-03-31 $-0
2017-12-31 $-0
2017-09-30 $-0
2017-06-30 $-0
2017-03-31 $-0
2016-12-31 $-0
2016-09-30 $-0
2016-06-30 $-1
2016-03-31 $-0
2015-12-31 $-0
2015-09-30 $-0
2015-06-30 $-4
2015-03-31 $-0
2011-12-31 $-0
2011-09-30 $-0
2011-06-30 $-0
2011-03-31 $-0
2010-12-31 $-0
2010-09-30 $-0
2010-06-30 $-0
2010-03-31 $1
2009-12-31 $-0
2009-09-30 $-3
2009-06-30 $-0
2009-03-31 $-1
2008-12-31 $-1
2008-09-30 $-0
2008-06-30 $-0
2008-03-31 $-0
2007-12-31 $-0
2007-09-30 $-0
2007-06-30 $-0
2007-03-31 $-0
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.041B $0.001B
INVO Bioscience is a medical device company, headquartered in Beverly, Massachusetts, focused on creating simplified, lower cost treatment options for patients diagnosed with infertility. It engages in the development and manufacture of its lead product, INVOcell, a novel medical device used in infertility treatment that enables egg fertilization and early embryo development in the woman's vaginal cavity. The company was founded by Claude Ranoux, MD, a noted expert in the field of reproductive health, infertility and embryology. INVO Bioscience focuses on selling its product to IVF centers and physicians through distributors, as well as directly to physicians in Europe, Canada, Latin America, and the Middle East.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $128.216B 8.54
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.812B 20.00
Biohaven Pharmaceutical Holding (BHVN) United States $8.815B 0.00
Emergent Biosolutions (EBS) United States $2.763B 6.66
Arcus Biosciences (RCUS) United States $2.321B 0.00
Myovant Sciences (MYOV) United Kingdom $1.993B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.769B 0.00
Zymeworks (ZYME) Canada $1.152B 0.00
Ambrx Biopharma (AMAM) United States $0.431B 0.00
SQZ Biotechnologies (SQZ) United States $0.346B 0.00
Enzo Biochem (ENZ) United States $0.188B 18.43